When surgery is contraindicated or incomplete resection is anticipated, denosumab (a RANKL inhibitor) can suppress osteoclastic activity and shrink cyst volume; nevertheless, prolonged surveillance is essential because recurrence and incomplete ossification remain concerns, particularly in active, expansile lesions that jeopardize structural integrity (22). The gene discussed is TNFSF11; the disease is cyst.